Välkommen till Medivir
Open/Close

12 Mar 12:00

Summary of the R&D update held earlier today

11 Mar 14:00

Medivir outlicenses MIV-210 to Daewoong Pharmaceutical Co. Ltd. for clinical development

more news »


Latest reports
FINANCIAL STATEMENT, 1 JANUARY – 31 DECEMBER 2009
INTERIM REPORT, 1 JANUARY – 30 SEPTEMBER 2009

Forthcoming reports 2010
The Three-month Interim Report will be published on 29 April
The Annual General Meeting will be held on 29 April
The Six-month Interim Report will be published on 8 July
The Nine-month Interim Report will be published on 22 October

Medivir had a very satisfactory 2009

Our cold sore product secured market approval in the US and Europe and is well positioned for launch. This will take place under the Xerclear™ trademark in Europe, and under the Xerese™ trademark in the US during 2010. We made major advances in our existing infectious diseases portfolio in partnership with Tibotec/Johnson & Johnson and are looking forward to the clinical results from phase IIb trials on TMC435 in 2010. Read more